Steris PLC 10-Q quarterly reports

Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.

NYSE
STERIS plc announced a 7.3% increase in total revenues for the first quarter of fiscal year 2027, reaching $1,492.7 million, driven by volume and pricing across its segments.
NYSE
STERIS plc reported robust financial performance for the third quarter and first nine months of fiscal 2026, driven by increased volume and pricing across all segments.
NYSE
STERIS plc reports robust Q2 and H1 fiscal 2026 results with significant revenue and operating income growth across all segments, driven by volume and pricing.
NYSE
STERIS plc reported robust first-quarter fiscal 2026 results with significant revenue growth, improved profitability, and strong cash flow, driven by all three segments and reduced debt.
NYSE
STERIS plc announces a 5.6% increase in revenue for Q3 2025, driven by organic growth and strategic initiatives, including a restructuring plan to enhance profitability.
NYSE
STERIS plc's second quarter of fiscal year 2025 saw a 7.3% increase in revenue, driven by the Healthcare segment, while the company progresses with its restructuring plan.
NYSE
STERIS plc's first quarter fiscal 2025 results show revenue growth and a strategic restructuring plan aimed at enhancing profitability.
NYSE
STERIS plc's Q3 results show a significant revenue increase driven by acquisitions and strong performance across multiple segments.